“In the first quarter of 2025, Acumen’s (ABOS) strong execution continued to build on the momentum achieved in 2024. ALTITUDE-AD, our Phase 2 study investigating the efficacy, safety and tolerability of sabirnetug for the treatment of early AD, is fully enrolled and we expect topline results in late 2026,” said Daniel O’Connell, Chief Executive Officer of Acumen. “This sizable 542-participant study enrolled quickly, a testament to the interest in sabirnetug’s high selectivity for toxic amyloid beta oligomers from clinical trial investigators, patients and caregivers alike. The fundamentals of our clinical development plan and underlying business are strong, and we look forward to building on our positive momentum throughout the year.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABOS:
- Acumen presented results from pTau217 assay in Phase 2 ALTITUDE-AD trial
- Acumen Pharmaceuticals’ Earnings Call: Progress Amid Challenges
- Acumen Pharmaceuticals’ Promising Alzheimer’s Strategy Earns Buy Rating with Revised Price Target
- Acumen price target lowered to $11 from $15 at H.C. Wainwright
- Acumen price target lowered to $10 from $12 at BofA